Following findings that eight patients experienced significant, non-life threatening heart incidents, Teva Pharmaceutical Industries Ltd. And Active Biotech AB have ceased phase-2 and phase-3 clinical trial studies of Laquinimod. Laquinimod is used for the treatment of multiple sclerosis and Huntington Disease. The U.S. Food and Drug Administration (FDA) requires phase 3 clinical trial completion before a drug can obtain approval for distribution on a large scale.
These heart-related incidents occurred after high doses of the drug were administered as part of the Bravo (Phase-2) and Concerto (Phase-3) phases of the study. Both companies have stated that only low-dose and placebo components of the study phases will continue moving forward.
The study includes 2,199 patients and was set for completion after 24-months of use or the reports of 260 significant health-related events. The dosage responsible for the significant cardiovascular events is the 1.2mg/day dosage.
If you or someone you know has been experienced a significant heart-related event during the Bravo or Concerto phases of these studies, due to the use of Laquinimod, contact Harman Law, at 1-888-55-HARMAN, to discuss potential legal recourse and possible monetary compensation. At Harman Law, the initial consultation comes at no cost to you.
Posted on behalf of
